HRES 507119th CongressIntroduced

Expressing support for the designation of June 10 as "FSGS Awareness Day".

Introduced: Jun 12, 2025

Healthcare

Standard Summary

Comprehensive overview in 1-2 paragraphs

This resolution (H. Res. 507) expresses the House’s support for designating June 10 as “FSGS Awareness Day.” FSGS stands for focal segmental glomerulosclerosis, a rare kidney disease characterized by scarring that can lead to kidney failure, dialysis, or transplant. The resolution highlights the burden of FSGS, including rapid progression to kidney failure, high rates of transplant recurrence, and significant costs to the health care system. It acknowledges disparities, particularly among African American communities, and notes ongoing research and emerging therapies. The measure is purely symbolic (a non-binding expression of Congress’ sentiment) and does not create, fund, or mandate any new programs.

Key Points

1Expresses support for designating June 10 as “FSGS Awareness Day” to raise awareness, support patients and families, and promote better diagnosis and access to future treatments.
2Outlines the burden of FSGS, including rapid progression to kidney failure, high likelihood of dialysis or transplant within 5–10 years, and recurrence in transplanted kidneys.
3Highlights disparities and genetic risk factors (notably APOL1 variants more common in individuals of African ancestry) contributing to higher impact in Black communities.
4Emphasizes ongoing research and hopeful advances, including clinical trials and potential therapies that could delay disease progression and improve biomarker use (proteinuria) as an indicator of treatment response.
5Acknowledges the role of patient advocates, healthcare providers, researchers, industry, and fundraising efforts (e.g., the Tampa Pig Jig) in supporting awareness and research; states the resolution is a non-binding expression of Congressional support.

Impact Areas

Primary group/area affected- People living with FSGS and their families, plus caregivers and health care providers (nephrologists), who benefit from increased awareness, earlier diagnosis, and potential future treatments.Secondary group/area affected- Minority communities, especially African Americans, who are disproportionately affected due to higher risk variants and disparities in access to care.- Health care payors (Medicaid, Medicare, private insurers) due to the disease’s high treatment costs and potential shifts in emphasis toward early detection and management.Additional impacts- Public awareness and education: The designation can catalyze awareness campaigns, patient education, and community outreach around June 10 each year.- Policy and research context: While non-binding, the resolution may support advocacy efforts for increased attention to FSGS research funding, access to nephrology care, and development of therapies; it does not authorize new programs or funding.- No fiscal impact or regulatory changes: The resolution does not appropriate funds, impose requirements, or change existing law. It is a symbolic expression of Congress’ support.FSGS (focal segmental glomerulosclerosis): a kidney disease where scar tissue forms in parts of the kidney’s filtering units, often leading to kidney failure.Glomerulonephritis: general term for kidney diseases involving inflammation of the kidney’s filtering units.APOL1 gene: genetic variants associated with higher risk of certain kidney diseases, disproportionately found in people of African ancestry.Recurrence: FSGS coming back in a transplanted kidney, a known challenge for patients who receive a transplant.

Generated by gpt-5-nano on Oct 3, 2025